News
Stay up to date with CellCentric and follow us on Twitter
Key information, updates and news can be found through our tweets
New oral cancer drug inobrodib is making a difference. Made possible by the combined efforts of patients, physicians, scientists & hospital staff. Thank you. #WorldCancerDay
Many thanks @Labiotech_eu for featuring @CellCentric’s CEO, Will West. Special article on improving cancer care, ahead of #WorldCancerDay2023 https://www.labiotech.eu/in-depth/how-can-cancer-care-be-improved/
Delighted to now have Dave as part of the wider CellCentric team, supporting inobrodib product supply, as we prepare for scale up, pivotal studies.
New oral cancer drug inobrodib is making a difference. Made possible by the combined efforts of patients, physicians, scientists & hospital staff. Thank you. #WorldCancerDay
Many thanks @Labiotech_eu for featuring @CellCentric’s CEO, Will West. Special article on improving cancer care, ahead of #WorldCancerDay2023 https://www.labiotech.eu/in-depth/how-can-cancer-care-be-improved/
Delighted to now have Dave as part of the wider CellCentric team, supporting inobrodib product supply, as we prepare for scale up, pivotal studies.
PODCAST: https://www.cellcentric.com/wp-content/uploads/2023/01/Optimumcellcentric-podcast_1_Mix4_AP_No-Intro-and-Outro.mp3 Discusses recent inobrodib clinical trial data with key opinion leaders and hears from a multiple myeloma patient.
Many thanks @CRUK_MI @somervaillelab for highlighting the patient experience; clinical trial with inobrodib treating blood cancers. In today’s Express.
Will & Tomasz in San Francisco for #jpm2023. Sharing progress on inobrodib, our oral p300/CBP inhibitor drug, advancing in haem & solid cancer clinical trials.
New oral cancer drug inobrodib is making a difference. Made possible by the combined efforts of patients, physicians, scientists & hospital staff. Thank you. #WorldCancerDay
Many thanks @Labiotech_eu for featuring @CellCentric’s CEO, Will West. Special article on improving cancer care, ahead of #WorldCancerDay2023 https://www.labiotech.eu/in-depth/how-can-cancer-care-be-improved/
Delighted to now have Dave as part of the wider CellCentric team, supporting inobrodib product supply, as we prepare for scale up, pivotal studies.
PODCAST: https://www.cellcentric.com/wp-content/uploads/2023/01/Optimumcellcentric-podcast_1_Mix4_AP_No-Intro-and-Outro.mp3 Discusses recent inobrodib clinical trial data with key opinion leaders and hears from a multiple myeloma patient.
Many thanks @CRUK_MI @somervaillelab for highlighting the patient experience; clinical trial with inobrodib treating blood cancers. In today’s Express.
Will & Tomasz in San Francisco for #jpm2023. Sharing progress on inobrodib, our oral p300/CBP inhibitor drug, advancing in haem & solid cancer clinical trials.
New oral cancer drug inobrodib is making a difference. Made possible by the combined efforts of patients, physicians, scientists & hospital staff. Thank you. #WorldCancerDay
Many thanks @Labiotech_eu for featuring @CellCentric’s CEO, Will West. Special article on improving cancer care, ahead of #WorldCancerDay2023 https://www.labiotech.eu/in-depth/how-can-cancer-care-be-improved/
Delighted to now have Dave as part of the wider CellCentric team, supporting inobrodib product supply, as we prepare for scale up, pivotal studies.
PODCAST: https://www.cellcentric.com/wp-content/uploads/2023/01/Optimumcellcentric-podcast_1_Mix4_AP_No-Intro-and-Outro.mp3 Discusses recent inobrodib clinical trial data with key opinion leaders and hears from a multiple myeloma patient.
Many thanks @CRUK_MI @somervaillelab for highlighting the patient experience; clinical trial with inobrodib treating blood cancers. In today’s Express.
Will & Tomasz in San Francisco for #jpm2023. Sharing progress on inobrodib, our oral p300/CBP inhibitor drug, advancing in haem & solid cancer clinical trials.
Latest press releases
CellCentric presents early haem clinical data at ASH
CellCentric to present haem clinical data at ASH
